China Says Anti-Bribery Investigations Do Not Target Multinational Companies
This article was originally published in PharmAsia News
Executive Summary
Far from being an isolated incident, investigations into GSK sales practices have spread to Sanofi and Eli Lilly. As more manufacturers are pulled into China’s ongoing investigation into commercial bribery, observers can’t help but wonder whether multinational firms are the target.